Latest Bronchodilator Stories
LONDON, March 24, 2015 /PRNewswire/ -- Key Findings--Chronic obstructive pulmonary disorder (COPD) is the third leading cause of death in the United States, and is in fourth
-- In Quebec alone 386,000 people suffer from COPD and it is the fourth leading cause of death in Canada.
The COPD Market Will Fracture with the Continuing Entry of LABA/LAMAs and Other Later-to-Market Bronchodilators, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
RIDGEFIELD, Conn., Oct.
Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD,
MedicationDiscountCard.com offers Veramyst discount cards, along with discount cards for other similar medications.
BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat(®)*)5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious
LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium)
Each of the Emerging LABA/LAMA Fixed-Dose Combinations Has Advantages Over Current Therapies on Efficacy Measures, According to Findings from Decision Resources Group BURLINGTON, Mass., April
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.